Haihe Biopharma Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 133

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Latest Deal Amount
  • $426M

  • Investors
  • 40

Haihe Biopharma General Information

Description

Developer of oncology drugs designed to provide anti-tumor therapies for cancer patients. The company's technology utilizes lipid self-emulsifying drug delivery and preclinical evaluation platforms, enabling oncology patients to access small molecule inhibitors, oral solutions, anti-tumor therapies, oncology drugs, chemotherapy formulations and pharmaceutical products.

Contact Information

Formerly Known As
Haihe Pharmaceutical, RMX Pharmaceutical Technology
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • No. 865, Zuchongzhi Road
  • Pudong New Area
  • Shanghai, 201203
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • No. 865, Zuchongzhi Road
  • Pudong New Area
  • Shanghai, 201203
  • China
+86 021

Haihe Biopharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Haihe Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. IPO 28-May-2026 $426M Announced Clinical Trials - General
13. Secondary Transaction - Private 01-Mar-2026 Completed Clinical Trials - General
12. Later Stage VC 01-Dec-2025 Completed Clinical Trials - General
11. Secondary Transaction - Private 01-Nov-2023 Completed Clinical Trials - General
10. Later Stage VC (Series C) 01-Jun-2023 Completed Clinical Trials - General
9. IPO 21-Sep-2021 Cancelled Clinical Trials - General
8. Later Stage VC (Series B) 20-Jul-2020 Completed Clinical Trials - General
7. Later Stage VC 10-Jul-2020 Completed Clinical Trials - General
6. Secondary Transaction - Private 03-Jul-2020 $147M Completed Clinical Trials - General
5. Secondary Transaction - Private 23-Jun-2020 $147M Completed Clinical Trials - General
To view Haihe Biopharma’s complete valuation and funding history, request access »

Haihe Biopharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 128,343,351 $0.08 $1.32 1x $1.32 0.96%
Ordinary 83,826,637 $0.08 $0.08 1x $0.08 10.45%
To view Haihe Biopharma’s complete cap table history, request access »

Haihe Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of oncology drugs designed to provide anti-tumor therapies for cancer patients. The company's technology utili
Drug Discovery
Shanghai, China
133 As of 2025

Vienna, Austria
 

Karachi, Pakistan
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Haihe Biopharma Competitors (12)

One of Haihe Biopharma’s 12 competitors is Pfizer (Vienna), a Corporation company based in Vienna, Austria.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pfizer (Vienna) Corporation Vienna, Austria
Pfizer Pakistan Corporation Karachi, Pakistan
Gilead Formerly VC-backed Foster City, CA
Merck & Co. Corporation Rahway, NJ
Cardurion Venture Capital-Backed Burlington, MA
You’re viewing 5 of 12 competitors. Get the full list »

Haihe Biopharma Patents

Haihe Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2019170063-A1 Indolizine compounds, preparation method and use thereof Inactive 06-Mar-2018
WO-2019170055-A1 Compounds having cdk4/6 kinase inhibitory activity, pharmaceutical composition thereof and use thereof Inactive 05-Mar-2018
CA-3090439-A1 Compound having bet inhibitory activity and preparation method and use therefor Pending 06-Feb-2018
EP-3750885-A1 Compound having bet inhibitory activity and preparation method and use therefor Inactive 06-Feb-2018
EP-3750885-A4 Compound having bet inhibitory activity and preparation method and use therefor Inactive 06-Feb-2018 C07D471/04
To view Haihe Biopharma’s complete patent history, request access »

Haihe Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Haihe Biopharma Investors (40)

Investor Name Investor Type Holding Investor Since Participating Rounds
Warburg Pincus PE/Buyout Minority
Deluxe Family Company Corporation Minority
Hangzhou Tigermed Consulting Company Corporation Minority
Ciit Asset Management Asset Manager
Hangzhou Lula Asset Management Growth/Expansion Minority
You’re viewing 5 of 40 investors. Get the full list »

Haihe Biopharma FAQs

  • When was Haihe Biopharma founded?

    Haihe Biopharma was founded in 2011.

  • Where is Haihe Biopharma headquartered?

    Haihe Biopharma is headquartered in Shanghai, China.

  • What is the size of Haihe Biopharma?

    Haihe Biopharma has 133 total employees.

  • What industry is Haihe Biopharma in?

    Haihe Biopharma’s primary industry is Drug Discovery.

  • Is Haihe Biopharma a private or public company?

    Haihe Biopharma is a Private company.

  • What is Haihe Biopharma’s current revenue?

    The current revenue for Haihe Biopharma is .

  • How much funding has Haihe Biopharma raised over time?

    Haihe Biopharma has raised $495M.

  • Who are Haihe Biopharma’s investors?

    Warburg Pincus, Deluxe Family Company, Hangzhou Tigermed Consulting Company, Ciit Asset Management, and Hangzhou Lula Asset Management are 5 of 40 investors who have invested in Haihe Biopharma.

  • Who are Haihe Biopharma’s competitors?

    Pfizer (Vienna), Pfizer Pakistan, Gilead, Merck & Co., and Cardurion are some of the 12 competitors of Haihe Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process